Santos Marcelo A M, Souto Francisco J D
School of Medical Sciences, Federal University of Mato Grosso, Cuiabá, Brazil.
BMC Public Health. 2007 Mar 12;7:32. doi: 10.1186/1471-2458-7-32.
Hepatitis C virus (HCV) is a significant problem for patients undergoing hemodialysis therapy. This situation has never been studied in Mato Grosso state, central Brazil. This study was conducted aiming to estimate the prevalence of the anti-HCV and the incidence of seroconversion in the main metropolitan region of the state.
433 patients from the six hemodialysis units were interviewed and anti-HCV was tested by a third-generation enzyme immunoassay. An open cohort of patients who tested negative for anti-HCV at the entry of the study was created and seroconversions was assessed monthly. The staff responsible for the units were interviewed to assess whether the infection control measures were being followed. Logistic and Cox regression analysis were performed in order to assess risk factor to HCV.
The entry on the study took place between January 2002 and June 2005. 73 out of 433 (16.9%, CI 95%: 13.3-20.8) was found to be anti-HCV reactive. The multivariate analysis indicated as risk factors associated to anti-HCV the duration of the hemodialysis treatment, the number of transfusions received, and the unit of treatment. An open cohort of 360 patients who tested negative for anti-HCV was created, with a following average of 24 (+/- 15) months. Forty seroconversions were recorded corresponding to an incidence density of 4.6/1000 patient-months, ranges 0 to 30 among the units. Cox regression indicated the time of hemodialysis (RR = 2.2; CI 95%: 1.1-4.6; p < 0.05) and the unit where treatment was performed (RR = 42.4; CI 95%: 9.9-180.5; p < 0.05) as risk factors for seroconversion. The three units with highest anti-HCV prevalence and incidence were identified as those that more frequently failed to apply control measures.
The study demonstrated high prevalence and incidence of anti-HCV in some of the hemodialysis units. Time on hemodialysis therapy was an independent factor associated to HCV. Blood transfusion was associated with anti-HCV in initial survey but was not important in incident cases. Failure of applying control measures was more evident in units with the highest HCV prevalence and incidence. The results suggest that nosocomial transmission was the main spread factor of HCV in the studied population.
丙型肝炎病毒(HCV)对于接受血液透析治疗的患者而言是一个重大问题。巴西中部马托格罗索州从未对这种情况进行过研究。本研究旨在估算该州主要大都市地区抗-HCV的患病率以及血清转化的发生率。
对来自六个血液透析单位的433名患者进行了访谈,并通过第三代酶免疫测定法检测抗-HCV。创建了一个在研究开始时抗-HCV检测呈阴性的患者开放队列,并每月评估血清转化情况。对各单位负责人员进行了访谈,以评估是否遵循了感染控制措施。进行了逻辑回归和Cox回归分析,以评估HCV的危险因素。
研究于2002年1月至2005年6月期间开展。433名患者中有73名(16.9%,95%置信区间:13.3 - 20.8)抗-HCV反应呈阳性。多变量分析表明,与抗-HCV相关的危险因素为血液透析治疗的持续时间、接受输血的次数以及治疗单位。创建了一个由360名抗-HCV检测呈阴性的患者组成的开放队列,平均随访24(±15)个月。记录到40次血清转化,对应发病率密度为4.6/1000患者-月,各单位范围为0至30。Cox回归表明血液透析时间(相对风险 = 2.2;95%置信区间:1.1 - 4.6;p < 0.05)以及进行治疗的单位(相对风险 = 42.4;95%置信区间:9.9 - 180.5;p < 0.05)是血清转化的危险因素。确定抗-HCV患病率和发病率最高的三个单位是那些最常未实施控制措施的单位。
该研究表明部分血液透析单位抗-HCV的患病率和发病率较高。血液透析治疗时间是与HCV相关的一个独立因素。在初始调查中输血与抗-HCV相关,但在发病病例中并不重要。在HCV患病率和发病率最高的单位,未实施控制措施的情况更为明显。结果表明医院内传播是所研究人群中HCV的主要传播因素。